文献速递血栓与止血

妊娠期预防性使用低分子肝素与巨大儿的相关性:渥太华与金斯顿出生队列分析

Association between prophylactic low-molecular-weight heparin use in pregnancy and macrosomia: analysis of the Ottawa and Kingston birth cohort.
PubMed 文献 · J Thromb Haemost · 2019-01-08

该研究基于渥太华与金斯顿出生队列,纳入7519名孕妇,其中59名(0.78%)妊娠期使用低分子肝素。采用粗化精确匹配校正偏倚与混杂后,未发现低分子肝素使用与大于胎龄儿(LGA)存在显著关联,探索性结果间接提示不增加LGA风险。

要点

  • 妊娠期使用低分子肝素者共59例,占0.78%。
  • 未校正分析中LGA的OR为1.02(95%CI 0.48-2.16;P=0.96)。
  • 匹配校正后OR为1.15(95%CI 0.49-2.71),无显著关联。

核心结论

  • 探索性结果间接提示妊娠期使用低分子肝素者不增加大于胎龄儿风险。

研究设计与样本

  • 对渥太华与金斯顿(OaK)出生队列进行分析,共纳入7519名孕妇。
  • 59名孕妇妊娠期使用低分子肝素(0.78%)。
  • 采用粗化精确匹配(CEM)方法校正偏倚与混杂。

主要发现

  • 使用低分子肝素者BMI(P=0.0001)、年龄(P=0.0001)和产次(P=0.02)显著更高。
  • 使用低分子肝素者孕周较短(37.7±2.0 vs 39.2±2.0,P<0.0001),为医源性结果。
  • 未校正分析中LGA的OR为1.02(95%CI 0.48-2.16;P=0.96)。
  • 匹配样本校正母亲年龄、BMI和孕周后OR为1.15(95%CI 0.49-2.71)。

关键数值与推荐

  • LGA定义为大于第10百分位(>10%ile)。
  • 未校正分析OR=1.02(95%CI 0.48-2.16;P=0.96)。
  • 匹配校正后OR=1.15(95%CI 0.49-2.71)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文称结果为探索性(exploratory)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Essentials Low-molecular-weight heparin (LMWH) is used to prevent venous thromboembolism (VTE) in pregnancy. We evaluated the association between LMWH and large for gestational age (LGA) infants. We found no significant associations between LMWH use and LGA. LMWH does not appear to increase the risk for the delivery of an LGA infant. SUMMARY: Background Low-molecular-weight heparin (LMWH), an anticoagulant, is the recommended drug for thromboprophylaxis and treatment of venous thromboembolism (VTE) in pregnancy. During pregnancy, LMWH is routinely prescribed to mothers with an increased risk of VTE or with a history of thrombosis. Although clinical reports of larger offspring born to women administered LMWH have been noted, no studies to date have evaluated or associated the use of LMWH and large for gestational age (LGA) infants. Objectives To determine whether there is an association between LMWH usage in mothers and the prevalence of LGA. Patients/Methods We performed an analysis of the Ottawa and Kingston (OaK) Birth Cohort and report characteristics of LMWH and association LGA (> 10%ile). We used coarsened exact matching (CEM) methods to account for bias and confounding. Results A total of 7519 women from the OaK Birth Cohort were included; 59 were administered LMWH during pregnancy (0.78%). Mothers prescribed LMWH had significantly greater BMI (P = 0.0001), age (P = 0.0001) and parity (P = 0.02). Gestational length was shorter among women administered LMWH compared to those without treatment (37.7 ± 2.0 vs. 39.2 ± 2.0, P < 0.0001), an iatrogenic finding. The odds ratio of an LGA delivery among women administered LMWH was 1.02 (95% confidence interval [CI], 0.48-2.16; P = 0.96) in unadjusted analyses and was 1.15 (95% CI, 0.49-2.71) in the matched sample adjusted for maternal age, BMI and gestational age. Conclusions These results, although exploratory, provide indirect evidence of no increased risk of LGA infants among women prescribed LMWH.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Lowry DE, Corsi DJ, White RR, et al. Association between prophylactic low-molecular-weight heparin use in pregnancy and macrosomia: analysis of the Ottawa and Kingston birth cohort. J Thromb Haemost. 2019. PMID: 30552749. doi:10.1111/jth.14358

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。